Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
Cristina Guarducci(Hospital of Prato), Rinath Jeselsohn(Harvard University)
Cited by 34
Related Papers
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
|npj Breast Cancer|2018|134
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
|Cancer Research|2023|15
Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer
|JCI Insight|2025|10
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
|npj Breast Cancer|2024|4